Anthrax, a severe infectious disease caused by the spore-forming bacterium Bacillus anthracis, has been a formidable adversary to humanity throughout history. Our company is dedicated to providing one-stop anthrax vaccine and therapeutic development solutions.
Introduction to Anthrax
Anthrax is a formidable infectious disease caused by the spore-forming bacterium Bacillus anthracis. This insidious pathogen can infect humans through various routes, including cutaneous, inhalation, and gastrointestinal exposure, leading to a spectrum of clinical manifestations that can rapidly progress to life-threatening systemic complications.
Historically, anthrax has posed a significant public health threat, responsible for countless deaths in both humans and livestock. Despite the development of effective diagnostic tools, antimicrobial therapeutics, and preventive measures, the persistent risk of anthrax as a potential bioweapon continues to drive the need for innovative research and advancements in vaccine and therapy development.
Fig. 1 The life cycle of Bacillus anthracis in nature. (Salinas-Estrella E., et al., 2022)
Vaccine Development for Anthrax
A key focus of anthrax vaccine research has been the exploration of the clonal nature of Bacillus anthracis. Specifically, the highly conserved pagA gene, which codes for the Protective Antigen (PA), has been a central target for vaccine development. This knowledge has enabled the creation of PA-based anthrax vaccines with broad-spectrum efficacy, capable of protecting a diverse range of animal species against geographically diverse B. anthracis isolates.
1955-1960
Brachman Field Evaluation Study
1999
Congressional Mandate for AVRP
2002
AVRP Enrollment Initiated
2008
Reduction of PrEP priming series and IM administration approved
2012
3-IM priming approved
Therapeutics Development for Anthrax
Extensive evaluations have been conducted on the susceptibility of Bacillus anthracis to a wide range of antibiotics, from penicillin and aminoglycosides to quinolones and carbapenems. This has led to the establishment of evidence-based recommendations for antibiotic therapy, tailored to the specific manifestations of anthrax, such as cutaneous, gastrointestinal, inhalation, and meningeal forms.
Moreover, researchers have explored the potential of adjunctive therapies, including the use of corticosteroids for managing edema, surgical interventions for debridement of infected tissues, and the integration of antitoxin therapeutics, such as polyclonal anthrax immune globulin and monoclonal antitoxins.
Please click on the link below to learn more about our company's one-stop therapy development services.
Our Services
At our company, we are committed to advancing the fight against anthrax through our comprehensive vaccine and therapy development services. Our expertise spans the entire spectrum, from drug discovery to preclinical research, ensuring that our clients have access to the latest advancements and industry-leading capabilities.
- Aerosol Exposure Models
- Transtracheal Injection Models
- Peroral Intubation Models
- Intranasal Inoculation Models
Optional Species: murine, rabbit, guinea pig, nonhuman primate, and rat
Our state-of-the-art preclinical research facilities are equipped with the latest technologies and staffed by a team of highly skilled scientists. We specialize in conducting rigorous animal studies to evaluate the safety, immunogenicity, and efficacy of anthrax vaccine candidates and therapeutic interventions. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.
References
- Salinas-Estrella Elizabeth, et al. "Bovine Anaplasmosis: Will there ever be an almighty effective vaccine?." Frontiers in Veterinary Science 9 (2022): 946545.
- Atif, Farhan Ahmad, Kashif Hussain, and Saba Mehnaz. "Strategies for prevention and control of anaplasmosis: at human-animal interface." Pakistan Journal of Agricultural Sciences 58.5 (2021).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
